Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | RHEB | Q15382 | 2/20 | 0.50 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 4/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.47 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.47 |
| ▸ | ITGAL | P20701 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | ADK | P55263 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 3/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12069204 | 0.88 | NPC1 (0.74) | NPC1RHEBBTKCA1CA2 | |
| SCHEMBL2534126 | 0.85 | KMT2A (0.59) | NPC1KMT2ARHEBAHRTRPA1 | |
| SCHEMBL2534386 | 0.84 | MAOA (0.47) | KMT2AAHRLTA4HNR4A2CYP2A6 | |
| SCHEMBL8868277 | 0.84 | MEN1 (0.58) | KMT2APRKCQAHRLTA4HNR4A2 | |
| SCHEMBL2534566 | 0.84 | AHR (0.63) | NPC1KMT2APRKCQAHRTRPA1 | |
| SCHEMBL8869295 | 0.84 | AHR (0.63) | NPC1KMT2ARHEBAHRLTA4H | |
| SCHEMBL13548693 | 0.83 | AHR (0.58) | NPC1PRKCQAHRTRPA1LTA4H | |
| SCHEMBL2535539 | 0.83 | ALDH1A1 (0.51) | NPC1KMT2AAHRLTA4HNR4A2 | |
| SCHEMBL13548685 | 0.83 | MEN1 (0.57) | NPC1KMT2APRKCQCYP2A6MAOA | |
| SCHEMBL18941156 | 0.82 | KDM4E (0.54) | NPC1KMT2AFLT3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034119-A1 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-02-05 | — | — | US | disclosed |
| WO-2025099444-A1 | N-Acetylserotonin (NAS) Analogues | Beckley Psytech Limited (GB) | 2025-05-15 | — | — | WO | disclosed |
| EP-4463442-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118613473-A | Compounds and compositions for treating disorders associated with STING activity | 艾福姆德尤股份有限公司 | 2024-09-06 | — | — | CN | disclosed |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-31 | — | — | US | disclosed |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-31 | — | — | US | disclosed |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-31 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| WO-1994014770-A1 | TRYPTAMINE ANALOGUES AS 5-HT1-LIKE AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-07-07 | — | — | WO | disclosed |
| EP-0548250-A4 | SUBSTITUTED BICYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY | — | 1993-10-27 | — | — | EP | disclosed |
| EP-0548250-A1 | SUBSTITUTED BICYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY. | RHONE POULENC RORER INT (US) | 1993-06-30 | — | — | EP | disclosed |
| US-5187283-A | Reacting indole(or derivatives) with organic hydroperoxide in presence of group 4,5 or 6 metals and removing water during reaction | MITSUI TOATSU CHEMICALS, INC. (JP) | 1993-02-16 | — | — | US | disclosed |
| EP-0487322-A1 | Process for the preparation of indigo compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1992-05-27 | — | — | EP | disclosed |
| US-5112987-A | Process for the preparation of indigo compounds | MITSUI TOATSU CHEMICALS, INC. (JP) | 1992-05-12 | — | — | US | disclosed |
| WO-1992004321-A1 | SUBSTITUTED BICYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-03-19 | — | — | WO | disclosed |
| US-4973706-A | OXIDATION OF INDOLE WITH HYDROPEROXIDE | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1990-11-27 | — | — | US | disclosed |
| EP-0368508-A2 | Process for the preparation of indigo compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-05-16 | — | — | EP | disclosed |
| US-4731353-A | METAL SALT OF INDOLE-2-CARBOXYLIC ACID COLOR DEVELOPER | KANZAKI PAPER MANUFACTURING COMPANY, LIMITED (JP) | 1988-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034119-A1 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS | HTR4, OPRM1, HTR7 | NPC1 1011/4885KMT2A 880/4885FLT3 3085/4885 |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | NPC1 859/4885KMT2A 3772/4885FLT3 1798/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | NPC1 3981/4885KMT2A 3083/4885FLT3 461/4885 |
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | NPC1 859/4885KMT2A 3772/4885FLT3 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.